-
Mechanistic Insights into the Anti-Glioma Effects of Exosome-Like Nanoparticles Derived from Garcinia Mangostana L.: A Metabolomics, Network Pharmacology, and Experimental Study
26 Apr 2025 16:45 GMT
… 5 However, the development of drug resistance and associated … likely to become oral medications.33 Lipinski/ … integrating metabolomics, network pharmacology, molecular docking, and … Treatment: drug Resistance and Novel Delivery Systems. Curr Med Chem …
-
LianChuang ZhiXue Liquid Enema Modulates the Macrophage Polarization of Ulcerative Colitis via Inhibiting the Jagged-1/Notch1 Signaling Pathway
26 Apr 2025 16:46 GMT
… ulcerative colitis,16 as they deliver the medication directly … to Lab of Systems Pharmacology www.tcmsp-e.com … .
LCZXL Enema Treatment Alleviates UC Development Effectively
Phenotypic changes … in treating mild-to-moderate ulcerative colitis. Open Med. 2025 …
-
Assessing the Knowledge and Prescription Practice of Gastroenterologists and Pharmacists Toward Probiotics in Saudi Arabia: An Electronic Survey-Based Study
26 Apr 2025 16:46 GMT
… meta-analysis of ulcerative colitis patients, probiotics induce … specific treatments, while 25.6% of the pharmacists would … Probiotics for treating acute infectious diarrhoea. Sao Paulo Med J. … randomized double-blind controlled trial: impact of probiotics on …
-
Combined Mulberry Leaf Polysaccharide-Caged Liposomes for Effective Oral Drug Delivery in Rat Model
25 Apr 2025 14:20 GMT
… portal circulation. Additionally, treatment with the pathway inhibitor … novel drug-caged liposome (MLP-CL) was developed to … treating diabetes and its complications. Am J Chin Med. … enhance its anti-ulcerative colitis effects. Pharmaceutics. 2021;13(12 …
-
Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults
25 Apr 2025 12:00 GMT
… treat adults with ulcerative colitis (UC).
Patients eligible for the drug … treat plaque psoriasis and psoriatic arthritis.
For the treatment of UC, the drug … therapeutic benefit to induction treatment.
The EC’s … .
In the maintenance trial, 45% of patients …
-
FDA Oks Penpulimab for First-Line Non-Keratinizing Nasopharyngeal Carcinoma
25 Apr 2025 01:21 GMT
… FDA has also approved single-agent penpulimab for the treatment … including pneumonitis, septic shock, colitis, and hepatitis (n = … , double-blind, multicenter trial in patients with recurrent … with penpulimab, and treatment continued until disease progression …
-
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
24 Apr 2025 22:54 GMT
Sanofi will halt the development of its oral tumour … double-blind, placebo-controlled trial enrolled 221 patients with moderate … disease (NCT06637631) and ulcerative colitis (NCT06867094).
A number of … best-selling drugs of all time. The drug gained approval …
-
FDA Approves Penpulimab-Kcqx for Indications in Nonkeratinizing Nasopharyngeal Carcinoma
24 Apr 2025 23:32 GMT
… multicenter phase 3 clinical trial AK105-304 (NCT04974398), … receiving penpulimab included pneumonitis, colitis, hepatitis, endocrinopathies, nephritis … , according to the FDA. Additionally, the recommended … in the First-line Treatment of Recurrent or Metastatic …
-
FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma
24 Apr 2025 21:13 GMT
… States Food and Drug Administration (FDA) has approved penpulimab … partially or completely to treatment.
Pneumonitis: lung inflammation. … 304, a multicenter trial of 291 patients … penpulimab-kcqx included pneumonitis, colitis, hepatitis, endocrinopathies, …
-
FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma
24 Apr 2025 20:40 GMT
… FDA decision came from the phase 3 AK105-304 trial … phase 2 AK105-202 trial (NCT03866967) in 125 … ) related to penpulimab treatment included pneumonitis, colitis, hepatitis, endocrinopathies, … nasopharyngeal carcinoma. News release. FDA. April 23, 2025. …
About
© 1995-2025